Russell Skibsted - Jan 9, 2023 Form 4 Insider Report for ALIMERA SCIENCES INC (ALIM)

Role: Chief Financial Officer & SVP
Signature: /s/ Russell Skibsted
Stock symbol: ALIM
Transactions as of: Jan 9, 2023
Transactions value $: $0
Form type: 4
Date filed: 1/10/2023, 03:29 PM
Previous filing: Sep 13, 2022
Next filing: Mar 28, 2023

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ALIM	Common Stock	Award	$0	+17.5K		$0.00	17.5K	Jan 9, 2023	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ALIM	Employee Stock Option (Right to Buy)	Award	$0	+52.5K		$0.00	52.5K	Jan 9, 2023	Common Stock	52.5K	$2.82	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The Reporting Person was awarded 17,500 shares of restricted common stock in connection with his service as an executive officer of the Issuer, which shares vest in four equal annual installments beginning January 9, 2024, so long as the Reporting Person's service as an employee of the Issuer is continuous from the Grant Date through the applicable anniversary thereof.
F2	Becomes exercisable: (a) with respect to 13,125 options, when the Reporting Person completes 12 months of continuous service with the Issuer, and (b) with respect to the remaining 39,375 options, in equal monthly installments over 36 months beginning one month after the vesting commencement date of January 9, 2024, so long as the Reporting Person's service as an employee of the Issuer is continuous from the Grant Date through the applicable vesting date.

Content

The Reporting Person was awarded 17,500 shares of restricted common stock in connection with his service as an executive officer of the Issuer, which shares vest in four equal annual installments beginning January 9, 2024, so long as the Reporting Person's service as an employee of the Issuer is continuous from the Grant Date through the applicable anniversary thereof.

Becomes exercisable: (a) with respect to 13,125 options, when the Reporting Person completes 12 months of continuous service with the Issuer, and (b) with respect to the remaining 39,375 options, in equal monthly installments over 36 months beginning one month after the vesting commencement date of January 9, 2024, so long as the Reporting Person's service as an employee of the Issuer is continuous from the Grant Date through the applicable vesting date.